Cure My Disease

Don't miss your cure!

 Log in / Sign up

New implant aims to fuse arthritic finger joints and ease pain

NCT ID NCT06546332

Disease control Sponsor: Keri Medical SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study is testing a device called KeriFuse® that is implanted into the finger joint to fuse the bones together. It is for people with arthritis in the last joint of the finger or thumb. The goal is to see if it reduces pain and successfully fuses the joint within three months. About 97 adults are taking part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KeriFuse® intramedullary arthrodesis implant (a device to fuse finger joints)
What this could lead to
If successful, this implant could provide a reliable option to reduce pain and restore stability in arthritic finger joints.
What could go wrong
This is a post-market study with no control group, so results may not prove superiority over other treatments. Risks include infection, implant failure, or incomplete bone fusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 97 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The intended target population for the KeriFuse® and associated instruments is an adult population requiring a surgical treatment claimed by the device and presenting bone quality deemed satisfactory by the surgeon.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years, * Patients that will have a surgery using a KeriFuse® implant in accordance with the approved labelling and IFU. Exclusion Criteria: * Pregnant or nursing women, * Patients with intellectual disabilities who cannot follow the instructions of their surgeon, * Patients with a contraindication to surgery and more specifically to the implantation of KeriFuse®, * Patients with acute or chronic infections, local or systemic, * Patients with sensitivities or allergies to the implant components (Nickel, Titanium).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease osteoarthritis, hand

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis

Contacts and locations

Locations

  • Centre Ostéo Articulaire Fleming

    Bourgoin, 38300, France

  • Centre de la main du Pays d'Aix

    Aix-en-Provence, 13090, France

  • Clinique Mutualiste Catalane

    Perpignan, 66000, France

  • Clinique Saint François

    Nice, 06000, France

  • Clinique de la Chataigneraie

    Beaumont, 63110, France

  • Clinique du Parc

    Périgueux, 24000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.